Parabilis’ path from POC to new indications and challenging targets

With clinical proof of concept in desmoid tumors and a $305 million crossover round, Parabilis has line of sight to Phase III, and a choice about where to place its next bets. In a conversation with BioCentury, CEO Mathai Mammen explains the path for zolucatetide and why new Helicon-based formats could reach targets small-molecule degraders haven’t.

Mammen, who is also president and chairman of Cambridge, Mass.-based Parabilis Medicines Inc., sat down with BioCentury at the J.P. Morgan Healthcare Conference last week to discuss the company’s decision framework: where to take zolucatetide beyond desmoid, when a combination-first strategy makes sense, and how the Helicon platform could differentiate as it expands into degraders, newer TAC formats, and possibly radiopharmaceuticals...